NEXSEN LIMITED - INITIAL PUBLIC OFFER (IPO) - CLOSED

NEXSEN LIMITED - INITIAL PUBLIC OFFER (IPO) - CLOSED




Nexsen Limited (Proposed ASX code: NXN)
Initial Public Offer (Offer)

Alpine Capital, the Lead Manager, has invited Marketech Focus clients to participate in the Initial Public Offer (Offer) for Nexsen Limited, a nano-biotechnology company developing lab-quality diagnostics and sensors that deliver results in minutes - no lab, no delays. Their modular platform combines advanced materials, biomarker discovery, and machine learning to create scalable, user-friendly tests with unmatched sensitivity and simplicity.  Nexsen’s platform is designed to power the next-generation of rapid diagnostics and sensors. Combining patented and proprietary technologies, smart design, and AI to deliver unmatched performance in a low-cost, scalable format. 
​
The Public Offer is an offer of 30,000,000 Shares at an issue price of $0.20 per Share to raise $6,000,000 (Public Offer). Oversubscriptions of up to a further 10,000,000 Shares at an issue price of $0.20 per Share to raise up to a further $2,000,000 may be accepted.  
​
Please note, the Company has received firm commitments in excess of the maximum $8 million sought and, as a result, scale backs are expected.



Bids for the Offer should be lodged by 5.00pm (AEST) on Thursday 11 September 2025. The Lead Manager reserves the right to close the offer early subject to demand.

Please review the prospectus before placing any bid.

Highlights

  • Developing a next-generation biosensing platform that combines ultra-bright nanoparticles, high-affinity bioreceptors, and modular lateral flow architecture to deliver lab-quality diagnostics in a low-cost, user-friendly format.
  • Nexsen utilises a versatile platform technology strategy, providing a launchpad for high-impact point of care and point of use testing.
  • The platform is designed for real-world environments where speed, simplicity and accuracy matter most. From maternity wards to homes, farms and border checkpoints, the Company delivers diagnostics and sensors that work wherever the challenge is.
  • RMIT and Nexsen have undertaken six years of R&D work to date in preparation for clinical validation and regulatory approval.
  • Clinical trials for lead GBS Rapid Sensor product due to commence within weeks of ASX listing, with first FDA submissions expected early CY 2026



Board & Management
​
Board of Directors

Nexsen Ltd is led by Board and management team with deep expertise across biotechnology, diagnostics, regulatory affairs and capital markets. They are united in their commitment to build a company that delivers value for shareholders while improving health outcomes for patients, clinicians, and communities around the world. This includes:


​
Advisory Board

Acknowledgement

By clicking “Submit Bid” on the website form, you acknowledge and agree that:

  • You have read and understood the terms and conditions to access the electronic version of the Prospectus; 
  • You are an Australian resident and you are requesting a copy of the Prospectus from within Australia;
    OR
    If you are a non-Australian resident, you have consulted your professional adviser as to whether any governmental or other consents are required or whether any other formalities need to be considered and followed before accessing the Prospectus.
Marketech clients can bid for the offer by clicking the link below and including account number and bid amount/shares.

In order to be eligible for this allocation, you need to have:
  1. a current subscription to the Marketech Focus platform;
  2. a Marketech trading account number and HIN;
  3. a Macquarie CMA linked to your trading account
  4. read and understood the Prospectus;
  5. Bids under the Offer must be for a minimum of $2,000 worth of Shares (10,000 Shares) and thereafter, in multiples of $500 worth of Shares (2,500 Shares).
Please note:
  1. The Company and Lead Manager reserve the right to close the book early and to deem any bid invalid;
  2. All bids which have not been withdrawn by the closing time of the offer will represent irrevocable commitments  to subscribe for a number of Securities up to the maximum amount for which a bid is made and will be capable of acceptance in full or in part by the Lead Manager, at its discretion;
  3. Marketech will be paid a fee on amounts raised under this offer.